Member Info for appletree1

The thresholds for disclosure for UK issuers are 3% and every percentage point thereafter. Dropping 1% down from say 8% to 7% is notifiable. Why GDP TR1 not filed yet? Sloppy admin.

Hi Rockz. For buying and trading OTC shares I am looking at the five listed here - https://www.stockbrokers.com/guides/pennystocks. Charles Schwab have a UK arm so may end up being my preferred choice. Trading on OTC still light today but at least Cannacord have raised their bid to 0.7 USD so the spread is now a bit narrower. Our broker B Riley is still the best on the offer at 1.0 USD but don't quote a bid price.

Thanks Starlight. I'm familiar with the history from investing in Tiziana since Feb 2020 . It looks like Accustem is too small for NASDAQ listing yet unless they have secured a major backer that we don't know about yet. Note that OTC is not NASDAQ OTC. OTC is a separate organization not affiliated to the NASDAQ. Unlike NASDAQ, the OTC is not an Exchange but a simpler market for unlisted stocks. OTC serves as a fall-back for stocks that de-list off NASDAQ and conversely a lot of UK companies listed on AIM start out by using ADRs on OTC to get a toe-hold in the US before they are eligible for NASDAQ. Accustem is no different. [ IMHO the move to Bermuda base and OTC-only was probably primarily done to save GC taxes since he is the majority share-holder. The company might have been financially stronger more quickly if it went the usual AIM then dual-list OTC ADR and then NASDAQ route]. NASDAQ eligibility will depend on Accustem capturing the attention of a major fund or waiting until they have built up the business to generate yearly revenue. From the recent news on OTC Accustem plan to build HQ and clinic in Phoenix as first stage of operation, though they still mention seeking CE marking in Europe. I don't think sizeable sales or the NASDAQ listing will happen for a while yet. That said, I suspect that this phase represents a buying opportunity for the adventurous prepared to brave the spread, exchange costs and broker issues to buy more before the company really starts to move but the inaccessibility of OTC means that most of us UK holders will continue to bottom-drawer this stock rather than add or sell, until NASDAQ eventually happens. For more info on Accustem's plans and SWOT review see the Form 10k SEC filing that they added on OTC two weeks ago.

Logically if he doesn't know privileged/insider info like assay results when he buys shares there is no insider trading breach, irrespective of the amount of time lag between the assay results issuing and him buying. So, if he receives the data Friday or next week then no problem. As for the 30 day closed period, I guess it just means that our last year end accounts wont be published in less than 30 days.

Already mentioned in earlier posts. He doesn't have the assays just yet but they could still drop any day.

OK. So, we have a hefty 34% spread and teeny daily volume on OTC at present and with the best bid price currently at just 0.66 USD mostly because none of us in UK/Europe can readily buy or sell OTC and Accustem haven't yet done any supportive presentations in the US to build the investor base there. Can we ask GC to dual list this on AIM? My gut feeling is that the MCAP would be multiples of this level already and with way more volume in a day if this were on AIM. Do we have/ should we have an investor action group for this (and Tiziana)?

Next line of approach is to ask US broker dealers rather than UK ones. Notable that the MPIDs on OTC are the likes of Cannacord who act as MMs on a lot of my UK stocks. Re the bid offer variance, clearly Cannacord is one of the better MPIDs and B Riley are currently giving the best offer at 1USD, while Cantor Fitzgerald is the black sheep dragging down the Bid to 0.25p yesterday. Want to find a way of buying from B Riley.

Gabriel Cerrone's Tiziana holdings are also mostly held via Panetta Partners Limited and Planwise Group Limited. If we were to follow the money-flow of his investments as a strategy then buying OTC shares of ACUT at the lows would make good sense. What do you make of the MPIDs on OTC Starknight? Is it possible that some MPIDS (dealers/ brokers) are giving massively better prices than others and if so how do we tap into that from UK?

Apart from resolving the current trading access question, one item we need to consider is the MCAP of the company at present to gauge how far off we are from NASDAQ eligibility and to begin to make our own decisions on fair value etc. According to Marketwatch the issued ACUT share capital is 11.34 Million shares and that tallies with OTC based on yesterdays closing price, ie MCAP currently is apparently about 11.4M USD. On assets and equity only basis (income not yet being generated) I cant see that NASDAQ listing would be happening any time soon unless a major background investment is being organized. As regards the set-up on OTC, looking at the OTC page for ACUT we have 8 MPIDs (? equivalent to our MM?) with bid offer prices widely varying - hence the volatility. https://www.otcmarkets.com/stock/ACUT/quote#level-2. NB. The OTC website is where we should all be looking to get our data from, not the NASDAQ webpage that just reflects a small snap-shot of the OTC trading status.

Maltopostiger, I get the frustration. We all feel it, but the consolidation is a trivial factor. In essence consolidation is just an admin change that doesn't alter our share of the company nor inherently alter our holdings value. Factors that do affect our holdings value are access (where they are tradeable and how), sentiment, fundamentals and news-flow of progress. [NB. I'm not 'advising' buying, just relaying the news that everyone missed (you are welcome) and musing on the potential opportunity and seeking feedback from anyone with recommendations on where to trade these OTC shares.] The lack of simple route for buying or selling for UK and European investors is possibly/probably holding the stock back for now. So far the tech was invented in, trialled in and being developed in Europe and yet we/most of us have no easy direct route to buy and sell shares in the company. (Will look into AJ Bell, thanks to Starknight).

.......Seems that OTCQB is the official home for Accustem for now while the team build the company to a level where they can subsequently list on NASDAQ. The OTC shareprice is at least a proper one (not pink slips anymore) and not like TLSA's unofficial OTC was before the NASDAQ launch. The ACUT shareprice on OTC has now recovered to 1 US Dollar . Hyper volatile though. Could be worth picking up more shares on dips. What platforms allow OTC trades???

Mot sure if someone posted this already but from the RNS on 14 April 2022 Accustem say the OTC listing has been upgraded to OTCQB but dont say anything about NASDAQ. Is the NASDAQ listing still in progress? Can we ask Wendy to confirm that the NASDAQ application is pending?

LONDON and PHOENIX, April 14, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a life sciences company dedicated to improving outcomes for patients with cancer, is pleased to announce its uplisting from the OTC Pink Sheets to the OTCQB® Venture Marketplace (the “OTCQB”). AccuStem will commence trading on the OTCQB at the market open today, April 14, 2022, under the ticker “ACUT.” The Company believes that the uplist will create greater visibility to retail and institutional investors, as well as further enhance trading liquidity.

The OTCQB is operated by OTC Markets Group Inc. and recognized by the U.S. Securities and Exchange Commission as a market providing public information for analysis and value of securities. The OTCQB is designed for emerging growth U.S. and international companies, subject to ongoing listing requirements that include remaining current in financial reporting, undergoing an annual verification and management certification process, meeting a minimum bid price, and other specific financial conditions.

“Listing on the OTCQB is another important milestone for AccuStem. This additional exposure will be valuable as we broaden our shareholder base and raise capital to fulfill our vision for the company- building innovative products that improve outcomes for patients diagnosed with cancer,” commented Wendy Blosser, CEO of AccuStem.

On the NASDAQ website page for the TLSA listing, by contrast, the entry on that line of the Key Data section states " Exchange : NASDAQ-GM" and also specifies the amount of the MCAP and other data items too and includes pre-market and after market trades. No such data is given on the ACUT page. On the trades section ACUT's page still says : "NASDAQ Real Time quotes are not available for OTCBB or Other OTC stocks" whereas on the TLSA listing page it shows the trades. So I don't believe ACUT is listed on the NASDAQ yet.

Denny, although ACUT is shown on NASDAQ's website it still shows as " Exchange : Other OTC". So, it still ain't listed on NASDAQ yet IMHO.

Yes, GCAT is Main Market, making it conform to more rigorous standards, but it is still a micro-cap on SETSqx - so In trading it behaves much like then AIM stocks that are also on SETSqx . For all the micro-cap stocks on SETSqx, whether on AIM or Main market, liquidity is critical and the market makers that control the SP will do what they feel they need to do in order to to meet their liquidity prime remit and there will always be a manipulated character (SP distortions and smoke-and-mirrors) as a result.

This website LSE (London South East) is out of kilter with the official LSE (London Stock Exchange) but firstly and more importantly the official LSE is out of kilter with GCAT. Do we have a clear point of contact with GCAT or do we need to have a short-list of the admin requests as well as the usual technical queries ready for the next public engagement?

Who has been had, Gold? The Federal deep find is acknowledged in the note, but expressly NOT included in their production forecasts or their 60p risked valuation YET. So according to the note even without that find we already have a minimum 3-bagger to 60p on a risked basis - and if the resource report for Federal deep due shortly looks promising the value multiplier from that will start to kick in leading eventually to a potential massive increase in the SP by the time the reserve report issues. Yes, patience is needed but everything is still to play for.

Bebeto, just to explain and in case you did not see the AGM notice PDF, it is in the company docs on Caracal's website. The Notes section first paragraph stipulates the issued share capital on the date of the AGM. Assuming that they were careful to be absolutely correct, the number in issue on 18 February 2022 was 1,824,978,590 shares. MCAP is shares in issue multiplied by official bid price. The London Stock Exchange's MCAP figure does not tally with GCAT's stated issued shares, presumably because some of the issued shares still have not been listed with the Stock Exchange yet.

Yes, per my previous comments, it looks like most of the performance shares have been issued, most of them already at 18th February, but still not yet been listed with the London Stock Exchange hence why I suspect that a TVR needs filing to get all the issued shares recorded properly/ listed.

For better accuracy in forecasts and comparisons re MCAP shouldn't we be using the 1,824,978,590 shares in issue number as at 18 February from our AGM? By the current 0.95p bid price our current MCAP is 17.34M. When GCAT update the LSE by TVR fully recording the February placing shares and all issued performance shares our MCAP is this (or slightly higher if the last two tranches of performance shares have issued after 18 Feb and now being recorded).